A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder

  • STATUS
    Recruiting
  • participants needed
    300
  • sponsor
    Sirtsei Pharmaceuticals, Inc.
Updated on 5 December 2021
body mass index
major depressive disorder

Summary

This is a Phase 2 clinical study evaluating the safety and effectiveness of SP-624 as compared to placebo in the treatment of adults with Major Depressive Disorder.

Details
Condition Major depression, Endogenous depression, major depressive disorder, major depressive disorders
Treatment Placebo, SP-624
Clinical Study IdentifierNCT04479852
SponsorSirtsei Pharmaceuticals, Inc.
Last Modified on5 December 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note